Dianthus Therapeutics (NASDAQ:DNTH) Shares Up 7.4% - Time to Buy?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) traded up 7.4% during mid-day trading on Monday . The stock traded as high as $20.31 and last traded at $20.95. 42,144 shares traded hands during mid-day trading, a decline of 84% from the average session volume of 259,438 shares. The stock had previously closed at $19.50.

Analyst Ratings Changes

DNTH has been the subject of several analyst reports. Guggenheim reiterated a "buy" rating and issued a $84.00 price objective on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Wedbush reaffirmed an "outperform" rating and set a $36.00 price objective on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Finally, HC Wainwright reiterated a "buy" rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Seven equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $54.33.

Dianthus Therapeutics Trading Up 2.1 %

The stock's fifty day moving average price is $19.97 and its 200 day moving average price is $22.88. The stock has a market cap of $696.17 million, a P/E ratio of -8.67 and a beta of 1.62.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last issued its quarterly earnings results on Tuesday, March 11th. The company reported ($0.81) EPS for the quarter, beating analysts' consensus estimates of ($0.85) by $0.04. The business had revenue of $1.33 million for the quarter, compared to analysts' expectations of $1.40 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. On average, analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current year.

Hedge Funds Weigh In On Dianthus Therapeutics

A number of large investors have recently bought and sold shares of the stock. TCG Crossover Management LLC bought a new position in Dianthus Therapeutics during the 4th quarter valued at approximately $32,735,000. Braidwell LP lifted its holdings in shares of Dianthus Therapeutics by 144.4% during the fourth quarter. Braidwell LP now owns 1,206,589 shares of the company's stock valued at $26,304,000 after purchasing an additional 712,902 shares during the last quarter. Vestal Point Capital LP boosted its holdings in Dianthus Therapeutics by 172.2% in the fourth quarter. Vestal Point Capital LP now owns 1,075,000 shares of the company's stock worth $23,435,000 after acquiring an additional 680,000 shares in the last quarter. Octagon Capital Advisors LP boosted its stake in Dianthus Therapeutics by 20.8% in the 4th quarter. Octagon Capital Advisors LP now owns 2,110,167 shares of the company's stock worth $46,002,000 after purchasing an additional 363,500 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. purchased a new stake in shares of Dianthus Therapeutics during the fourth quarter valued at approximately $3,924,000. 47.53% of the stock is owned by hedge funds and other institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.